Researchers are hoping to find a new alternative to traditional chemotherapy to help treat HER2-positive metastatic gastric cancer, with later line treatments providing limited results which also take a toll on already fragile patients. Results of the phase II DESTINY-Gastric01 trial showed trastuzumab deruxtecan can improve overall response and survival rates, while also avoiding some of the…
Suneel Kamath: Standing Strong: ASCO Honors Advocacy Commitment in Oncology / Advocacy Champion, affecting issues, ASCO, cancer, cancer community, Cancer
Tune in to learn about the current state of disease management and the potential of ctDNA testing to guide treatment decisions and monitor disease progression.
Tune in to learn about the current state of disease management and the potential of ctDNA testing to guide treatment decisions and monitor disease progression.
Scientific Reports – Plasma metabolomic differences in early-onset compared to average-onset colorectal cancer
Stomach cancer used to be a leading killer in the United States, and continues to have easy-to-mistake symptoms. Here’s when to talk to a doctor.
PURPOSE National Cancer Institute (NCI) and nonprofit organization (NPO) funding is critical for research and advocacy but may not be equitable across cancers. METHODS This…
PURPOSE National Cancer Institute (NCI) and nonprofit organization (NPO) funding is critical for research and advocacy but may not be equitable across cancers. METHODS This…
Outcome of DPYD variant allele carriers treated with dose-individualized fluoropyrimidine therapy.
Listen as Dr. Kamath talks about the challenges associated with early detection, the evolving landscape of screening guidelines, potential contributing factors to the rise of…
